Mechanical Thrombectomy for Pediatric Large Vessel Occlusions
Background Acute intracranial large vessel occlusion (LVO) is an important cause of morbidity and mortality among children; however, unlike in adults, no clinical trial has investigated the benefit of mechanical thrombectomy (MT) in pediatric LVO. Thus, MT remains an off-label procedure for pediatri...
Gespeichert in:
Veröffentlicht in: | Clinical neuroradiology (Munich) 2023-09, Vol.33 (3), p.635-644 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background Acute intracranial large vessel occlusion (LVO) is an important cause of morbidity and mortality among children; however, unlike in adults, no clinical trial has investigated the benefit of mechanical thrombectomy (MT) in pediatric LVO. Thus, MT remains an off-label procedure for pediatric stroke. Purpose To investigate the efficacy and safety of MT in pediatric LVO. Methods A systematic literature search was conducted in Ovid MEDLINE, Ovid Embase, Scopus, Web of Science, and Cochrane Central Register of Clinical Trials databases. Studies reporting safety and efficacy outcomes for endovascular treatment of pediatric LVO were included. Data regarding recanalization, functional outcome, symptomatic intracranial hemorrhage (sICH), and mortality were extracted from the included studies. Functional outcome was assessed with the modified Rankin scale (mRS). A fixed or random-effects model was used to calculate pooled event rates and 95% confidence intervals (CI). Results In this study 11 studies comprising 215 patients were included. The successful recanalization rate was 90.3% (95% CIâ¯= 85.77-95.11%), and complete recanalization was achieved in 52.7% (95% CIâ¯= 45.09-61.62%) of the cases. The favorable (mRSâ¯= 0-2) and excellent (mRSâ¯= 0-1) outcome rates were 83.3% (95% CIâ¯= 73.54-94.50%) and 59.5% (95% CIâ¯= 44.24-80.06%), respectively. The overall sICH prevalence was 0.59% (95% CIâ¯= 0-3.30%) and mortality rate was 3.2% (95% CIâ¯= 0.55-7.38%). Conclusion In our meta-analysis, MT demonstrated a promising safety and efficacy profile for pediatric patients, with consistently high efficacy outcomes and low complication rates. Our results support the utilization of MT in pediatric LVOs; however, prospective studies are still needed to further establish the role of pediatric MT as a first-line treatment strategy. |
---|---|
ISSN: | 1869-1439 1869-1447 |
DOI: | 10.1007/s00062-022-01246-y |